靶向MAGE-A4/A8的TCR双特异性T细胞衔接器治疗复发难治实体瘤的I期试验
IMA401是一种基于高亲和力TCR结构域、靶向HLA-A*02:01呈递的MAGE-A4/MAGE-A8肽段的下一代双特异性T细胞衔接受体,含低亲和力T细胞招募结构域和优化Fc段以延长半衰期。这项I期首次人体试验预设中期分析纳入61例晚期实体瘤患者,静脉给予IMA401(0.0066–2.5 mg)单药或联合帕博利珠单抗,未达到MTD,RP2D为1–2 mg每两周一次;RP2D下ORR为20%(8/41),头颈癌亚组ORR为29%(4/14),中位缓解持续时间8.8个月。
要点
- IMA401的RP2D为1–2 mg每两周一次,联合或不联合帕博利珠单抗。
- RP2D下ORR为20%(8/41),头颈癌亚组ORR为29%(4/14)。
- 最常见任何级别TRAE为细胞因子释放综合征(38%,仅1–2级)。
核心结论
- IMA401在RP2D下安全性可控,不良事件多为暂时性,并显示出初步抗肿瘤活性。
研究设计与样本
- IMA401是一种靶向MAGE-A4/MAGE-A8的TCR为基础的双特异性T细胞衔接受体。
- 这项I期首次人体试验预设中期分析纳入61例晚期实体瘤患者。
- 患者接受静脉IMA401 0.0066–2.5 mg,单药或联合帕博利珠单抗。
- 主要终点为确定单药及联合帕博利珠单抗的MTD和/或RP2D。
主要发现
- 按方案定义未达到MTD,RP2D为1–2 mg每两周一次。
- 最常见任何级别TRAE为细胞因子释放综合征(38%,仅1–2级)、暂时性淋巴细胞减少(33%)和可逆性中性粒细胞减少(31%)。
- 5例患者发生DLT事件,主要与中性粒细胞减少相关。
- 全部剂量水平疗效可评估人群(n=56)确认ORR为14%(8/56)。
- RP2D下跨15种适应症ORR为20%(8/41),头颈癌亚组ORR为29%(4/14),中位缓解持续时间8.8个月。
关键数值与推荐
- RP2D为1–2 mg每两周一次。
- RP2D下ORR为20%(8/41),头颈癌亚组ORR为29%(4/14)。
- 头颈癌亚组中位缓解持续时间为8.8个月。
- 细胞因子释放综合征发生率38%,均为1–2级。
临床怎么用
- IMA401在RP2D下可联合或不联合帕博利珠单抗用于晚期实体瘤。
- RP2D范围预用地塞米松后未再发生DLT。
- 细胞因子释放综合征多为1–2级,血液学毒性可逆。
局限性
- RP2D下ORR为事后分析。
- 疗效可评估人群包含低起始剂量患者。
- 在RP2D范围外2.5 mg剂量发生一例可能相关死亡(肺炎)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMA401 is a T cell receptor (TCR)-based next-generation bispecific T cell engaging receptor (TCER) targeting an HLA-A*02:01-presented peptide derived from MAGE-A4/MAGE-A8 with its high-affinity TCR-based domain, incorporating a low-affinity T-cell-recruiting domain and an optimized Fc domain to prolong half-life. In this prespecified interim analysis of a phase 1 first-in-human trial, 61 patients with advanced solid tumors received intravenous IMA401 (0.0066 mg-2.5 mg) with or without pembrolizumab. The primary endpoint was determination of the maximum tolerated dose (MTD) and/or recommended phase 2 dose (RP2D) of IMA401 monotherapy and in combination with pembrolizumab. Secondary objectives included safety and tolerability, antitumor activity and pharmacokinetics. The MTD was not reached as defined by the clinical trial protocol, and the RP2D was 1-2 mg IMA401 biweekly. Treatment-related adverse events (TRAEs) were well manageable; the most common any-grade TRAEs were cytokine release syndrome (38%, grades 1-2 only), transient lymphopenia (33%) and reversible neutropenia (31%). Five patients experienced dose-limiting toxicity (DLT) events primarily related to neutropenia. No further DLTs occurred in the RP2D range with dexamethasone premedication. One possibly-related death (pneumonia in a patient with rapidly progressing lung metastases) was reported outside RP2D at 2.5 mg IMA401. In the overall efficacy-evaluable population across all dose levels (n = 56), including low starting doses (from 0.0066 mg), the confirmed objective response rate (ORR) was 14% (8/56). In patients receiving IMA401 at the RP2D, an ORR of 20% (8/41) was observed across 15 different indications (post hoc analysis). In the largest subgroup of patients treated at RP2D, namely head and neck cancer, the ORR was 29% (4/14) with a median duration of response of 8.8 months. These findings show that the bispecific TCER platform has a manageable safety profile with mostly transient adverse events and promising antitumor activity at the RP2D of IMA401 with or without pembrolizumab. ClinicalTrials.gov identifier: NCT05359445 .
引用
- Wermke M, Ochsenreither S, Jaeger D, et al. MAGE-A4/MAGE-A8-targeted TCR-based bispecific T cell engager in recurrent and/or refractory solid tumors: a phase 1 trial. Nat Med. 2026. PMID: 42219399. doi:10.1038/s41591-026-04455-x
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。